Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Current Immunotherapy in Multiple Sclerosis
Immunology and Cell Biology 76:55-64, Bashir,K.&Whitaker,J.N., 1998
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
An Open-Label Trial of Combination Therapy With Interferon B-1a and Oral Methotrexate in MS
Neurol 58:314-317, Calabresi,P.A.,et al, 2002
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Multiple Sclerosis,Therapeutic Update
Arch Neurol 56:277-280, Tselis,A.C.&Lisak,R.P., 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Effect of Steroids on Gd-Enhancing Lesions Before & During Beta Interferon 1a Trtm in Relapsing Remitting MS
Neurol 50:403-406, Gasperini,C.,et al, 1998
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
NEJM 339:285-291, 3391998., Confavreux,C.,et al, 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998